Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications
暂无分享,去创建一个
Mohammed Shameem | A. Ambrogelly | Mark A Haverick | M. Shameem | Alexandre Ambrogelly | Mark Haverick | Selina Mengisen | S. Mengisen
[1] Bernhardt L Trout,et al. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding , 2011, mAbs.
[2] G. Gilliland,et al. Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.
[3] Ronald T Borchardt,et al. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. , 2007, Biochemistry.
[4] Dieter Söll,et al. Natural expansion of the genetic code. , 2007, Nature chemical biology.
[5] Bernhardt L. Trout,et al. Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.
[6] D. Ejima,et al. The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography. , 2007, Protein expression and purification.
[7] Liqiang Lisa Zhou,et al. Impact of short range hydrophobic interactions and long range electrostatic forces on the aggregation kinetics of a monoclonal antibody and a dual-variable domain immunoglobulin at low and high concentrations. , 2011, International journal of pharmaceutics.
[8] W. Xu,et al. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies , 2012, mAbs.
[9] Bernhardt L Trout,et al. Aggregation-prone motifs in human immunoglobulin G. , 2009, Journal of molecular biology.
[10] Alain Balland,et al. Separation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions. , 2008, Journal of chromatography. A.
[11] B. Yan,et al. O-fucosylation of an antibody light chain: characterization of a modification occurring on an IgG1 molecule. , 2008, Glycobiology.
[12] Aditya A Wakankar,et al. Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.
[13] A. Alpert. High-performance hydrophobic-interaction chromatography of proteins on a series of poly(alkyl aspart-amide)-silicas , 1986 .
[14] P. Declerck. Biosimilar monoclonal antibodies: a science-based regulatory challenge , 2013, Expert opinion on biological therapy.
[15] D. Goldenberg,et al. Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation. , 1992, Molecular immunology.
[16] Huub Schellekens,et al. Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.
[17] K. Büssow,et al. Fast identification of folded human protein domains expressed in E. coli suitable for structural analysis , 2004, BMC Structural Biology.
[18] J. Queiroz,et al. Hydrophobic interaction chromatography of proteins. , 2001, Journal of biotechnology.
[19] K. Inouye,et al. Single-step purification of F(ab')2 mu fragments of mouse monoclonal antibodies (immunoglobulins M) by hydrophobic interaction high-performance liquid chromatography using TSKgel ether-5PW. , 1993, Journal of biochemical and biophysical methods.
[20] Mingxiang Li,et al. Separation of oxidized variants of a monoclonal antibody by anion-exchange. , 2011, Journal of chromatography. A.
[21] Lei Zheng. Monoclonal Antibodies: Development, Delivery and Applications , 2015 .
[22] John F. Valliere-Douglass,et al. Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. , 2008, Analytical chemistry.
[23] K. Inouye,et al. Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW. , 1992, Journal of biochemical and biophysical methods.
[24] Marisa K Joubert,et al. Classification and Characterization of Therapeutic Antibody Aggregates , 2011, The Journal of Biological Chemistry.
[25] Bernhardt L Trout,et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.
[26] P. Tessier,et al. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. , 2012, Protein engineering, design & selection : PEDS.
[27] D. Ouellette,et al. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule , 2013, mAbs.
[28] B. Yan,et al. HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[29] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[30] C A Smith,et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.
[31] X. Geng,et al. Liquid chromatography of recombinant proteins and protein drugs. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[32] John R. Engen,et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars , 2012, Nature Reviews Drug Discovery.
[33] Å. Danielsson,et al. An adaptation of hydrophobic interaction chromatography for estimation of protein solubility optima. , 1997, Journal of pharmaceutical and biomedical analysis.
[34] Anthony Mire-Sluis,et al. Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.
[35] W. Xu,et al. Developability studies before initiation of process development , 2013, mAbs.
[36] R J Harris,et al. Heterogeneity of recombinant antibodies: linking structure to function. , 2005, Developments in biologicals.